{"id":190681,"date":"2024-06-05T22:23:15","date_gmt":"2024-06-06T03:23:15","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/100-of-cancer-patients-cured-long-term-in-remarkable-human-trial"},"modified":"2024-06-05T22:23:15","modified_gmt":"2024-06-06T03:23:15","slug":"100-of-cancer-patients-cured-long-term-in-remarkable-human-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/100-of-cancer-patients-cured-long-term-in-remarkable-human-trial","title":{"rendered":"100% of Cancer Patients Cured Long-Term in \u2018Remarkable\u2019 Human Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/100-of-cancer-patients-cured-long-term-in-remarkable-human-trial.jpg\"><\/a><\/p>\n<p>In what researchers have called an \u201cunprecedented\u201d response, a new drug that treats locally advanced rectal cancer has shown to have completely eradicated tumors in all 42 patients who took part in the Phase II trial.<\/p>\n<p>The drug, Jemperli (dostarlimab-gxly), had earlier shown great potential for eliminating mismatch repair deficient (dMMR) cancers, which make up 5\u201310% of colorectal cancers. Following the Phase II trial, the first 24 patients assessed showed a \u201csustained complete clinical response\u201d \u2013 no cancer evident \u2013 after an average of 26.3 months.<\/p>\n<p>\u201cThese findings demonstrate the potential of dostarlimab-gxly as a novel approach to treating locally advanced dMMR rectal cancer that leads to durable complete tumor regression without the need for life-altering treatment,\u201d said Dr Andrea Cercek, researcher and oncologist at the Memorial Sloan Kettering Cancer Center (MSK). \u201cAs a clinician, I\u2019ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In what researchers have called an \u201cunprecedented\u201d response, a new drug that treats locally advanced rectal cancer has shown to have completely eradicated tumors in all 42 patients who took part in the Phase II trial. The drug, Jemperli (dostarlimab-gxly), had earlier shown great potential for eliminating mismatch repair deficient (dMMR) cancers, which make up [\u2026]<\/p>\n","protected":false},"author":359,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-190681","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/190681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/359"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=190681"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/190681\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=190681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=190681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=190681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}